WO2011048491A3 - Amorphous rotigotine co-precipitates - Google Patents

Amorphous rotigotine co-precipitates Download PDF

Info

Publication number
WO2011048491A3
WO2011048491A3 PCT/IB2010/002844 IB2010002844W WO2011048491A3 WO 2011048491 A3 WO2011048491 A3 WO 2011048491A3 IB 2010002844 W IB2010002844 W IB 2010002844W WO 2011048491 A3 WO2011048491 A3 WO 2011048491A3
Authority
WO
WIPO (PCT)
Prior art keywords
precipitates
rotigotine
amorphous
methods
amorphous rotigotine
Prior art date
Application number
PCT/IB2010/002844
Other languages
French (fr)
Other versions
WO2011048491A2 (en
Inventor
Mayur Devjibhai Khunt
Udhaya Kumar
Nitin Sharadchandra Pradhan
Original Assignee
Actavis Group Ptc Ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actavis Group Ptc Ehf filed Critical Actavis Group Ptc Ehf
Priority to EP10784574.5A priority Critical patent/EP2490673A2/en
Publication of WO2011048491A2 publication Critical patent/WO2011048491A2/en
Publication of WO2011048491A3 publication Critical patent/WO2011048491A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed herein is a stable amorphous co -precipitate of (-)-(S)-5-hydroxy-2-[N-n- propyl-N-2-(2-thienyl)ethylamino]tetralin (Rotigotine) with pharmaceutically acceptable excipients, methods for the preparation, pharmaceutical compositions, and methods of treating thereof. Advantageously, the amorphous co-precipitates of rotigotine have improved physio chemical characteristics that assist in their effective bioavailability.
PCT/IB2010/002844 2009-10-19 2010-10-18 Amorphous rotigotine co-precipitates WO2011048491A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10784574.5A EP2490673A2 (en) 2009-10-19 2010-10-18 Amorphous rotigotine co-precipitates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2527/CHE/2009 2009-10-19
IN2527CH2009 2009-10-19

Publications (2)

Publication Number Publication Date
WO2011048491A2 WO2011048491A2 (en) 2011-04-28
WO2011048491A3 true WO2011048491A3 (en) 2011-12-29

Family

ID=43402066

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/002844 WO2011048491A2 (en) 2009-10-19 2010-10-18 Amorphous rotigotine co-precipitates

Country Status (2)

Country Link
EP (1) EP2490673A2 (en)
WO (1) WO2011048491A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014016842A1 (en) * 2012-07-23 2014-01-30 Symed Labs Limited Amorphous coprecipitates of rivaroxaban
WO2017106130A1 (en) 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Process for preparing pharmaceutical compositions

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084A1 (en) * 1998-03-30 1999-10-14 Lohmann Therapie Syst Lts Transdermal therapeutic system for the treatment of Parkinson's syndrome containing D2 agonist and method for its production
WO2002089778A2 (en) * 2001-05-08 2002-11-14 Schwarz Pharma Ag Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
WO2004058247A1 (en) * 2002-12-30 2004-07-15 Schwarz-Pharma Ag Device for the transdermal administration of a rotigotine base
US20090202647A1 (en) * 2008-02-11 2009-08-13 Mayur Devjibhai Khunt Solid form of racemic rotigotine
WO2009149955A2 (en) * 2008-06-13 2009-12-17 Ratiopharm Gmbh Method for the selection of a suitable adjuvant for the production of solid dispersions for pharmaceutical formulations
WO2010042152A2 (en) * 2008-10-06 2010-04-15 Mylan Technologies, Inc. Amorphous rotigotine transdermal system
EP2177217A1 (en) * 2007-07-06 2010-04-21 Beijing Kangbeide Pharmaceutical Technology Development Co., Ltd. Composition comprising rotigotine, its use and transdermal patch comprising the composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4564628A (en) 1983-01-03 1986-01-14 Nelson Research & Development Co. Substituted 2-aminotetralins
US4657925A (en) 1984-08-13 1987-04-14 Nelson Research & Development Co. Method and compositions for reducing the intraocular pressure of mammals
DE3479314D1 (en) 1984-05-22 1989-09-14 Nelson Res & Dev Substituted 2-aminotetralins and processes for synthesis
US4885308A (en) 1984-08-13 1989-12-05 Nelson Research & Development Co. Method and compositions for treatment of parkinsonism syndrome in mammals
US4968837A (en) 1989-07-28 1990-11-06 Ethyl Corporation Resolution of racemic mixtures
AU1613101A (en) 1999-11-23 2001-06-04 Aderis Pharmaceuticals, Inc. Improved process for preparing nitrogen-substituted aminotetralins

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084A1 (en) * 1998-03-30 1999-10-14 Lohmann Therapie Syst Lts Transdermal therapeutic system for the treatment of Parkinson's syndrome containing D2 agonist and method for its production
WO2002089778A2 (en) * 2001-05-08 2002-11-14 Schwarz Pharma Ag Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
WO2004058247A1 (en) * 2002-12-30 2004-07-15 Schwarz-Pharma Ag Device for the transdermal administration of a rotigotine base
EP2177217A1 (en) * 2007-07-06 2010-04-21 Beijing Kangbeide Pharmaceutical Technology Development Co., Ltd. Composition comprising rotigotine, its use and transdermal patch comprising the composition
US20090202647A1 (en) * 2008-02-11 2009-08-13 Mayur Devjibhai Khunt Solid form of racemic rotigotine
WO2009149955A2 (en) * 2008-06-13 2009-12-17 Ratiopharm Gmbh Method for the selection of a suitable adjuvant for the production of solid dispersions for pharmaceutical formulations
WO2010042152A2 (en) * 2008-10-06 2010-04-15 Mylan Technologies, Inc. Amorphous rotigotine transdermal system

Also Published As

Publication number Publication date
WO2011048491A2 (en) 2011-04-28
EP2490673A2 (en) 2012-08-29

Similar Documents

Publication Publication Date Title
AP2012006231A0 (en) Capsule formulation of pirfenidone and pharmaceutically acceptable excipients.
CL2017001853A1 (en) Treatment of cognitive disorders with (r) -7-chloro-n- (quinuclidin-3-yl) benzo [b] thiophene-2-carboxamide and pharmaceutically acceptable salts thereof (divisional application No. 1707-2016).
WO2010073124A3 (en) Processes for preparing highly pure rotigotine or a pharmaceutically acceptable salt thereof
WO2012083017A3 (en) Controlled release oral dosage forms of poorly soluble drugs and uses thereof
WO2007038506A3 (en) Method for the treatment of cachexia
TN2011000651A1 (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine their preparation and their therapeutic application
WO2011101863A3 (en) Extended release pharmaceutical compositions of lacosamide
WO2011076212A3 (en) Processes for the manufacture of a pharmaceutically active agent
WO2014027334A3 (en) Oral pharmaceutical composition in the form of microspheres and preparation method
WO2013106068A3 (en) Therapeutic compositions of specified herbal formulations and uses thereof
WO2011069076A3 (en) Sustained release donepezil formulations
WO2012058695A3 (en) Compositions of (-)-17-(cyclobutylmethyl) morphinan-3, 14-diol
WO2012024583A3 (en) Oxysterol compounds
WO2012099899A3 (en) Topical dermatological compositions for the treatment of acne
WO2011048491A3 (en) Amorphous rotigotine co-precipitates
WO2012018791A3 (en) Preparation of prasugrel hydrochloride
WO2011060253A3 (en) Methods of treating diseases, pharmaceutical compositions, and pharmaceutical dosage forms
WO2010143070A3 (en) Amorphous varenicline tartrate co-precipitates
EP2409685A3 (en) Orally-disintegrating formulations of prasugrel
WO2012010938A3 (en) Pharmaceutical composition of cefditoren pivoxil
WO2009013633A3 (en) Amorphous coprecipitates of atorvastatin pharmaceutically acceptable salts
WO2011139414A3 (en) Dexlansoprazole polymorphic forms
WO2011161223A3 (en) Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts
WO2011139255A3 (en) Pharmaceutical compositions comprising cefetamet
WO2014203156A3 (en) Pharmaceutical formulations and methods for oral delivery of biologically active ingredient

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10784574

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010784574

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE